LETC

LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies[1].

Product Specifications

CAS Number

[951131-13-8]

UNSPSC

12352005

Target

α-synuclein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/letc.html

Purity

98.30

Smiles

CCN(CC)C1=CC=C2C(SC3=C(N2)C=CC(N(CC)CC)=C3)=C1.Cl.Cl

Molecular Formula

C20H29Cl2N3S

Molecular Weight

414.44

References & Citations

[1]Karima Schwab, et al. LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy. Eur J Pharmacol. 2024 May 5:970:176505.